Healthcare-associated infections (HAIs) remain one of the most persistent and costly threats to hospital performance—driving up patient care costs, lowering safety grades, and eroding trust in hospital brands. In fact, recent studies place the financial burden of HAIs in U.S. hospitals between $28.4 and $45 billion annually, with Clostridioides difficile infections alone costing approximately $25,000 per case.
In our clinical brief, “Reducing the Cost and Risk of Healthcare-Associated Infections” we explore how hospitals can modernize their disinfection practices to protect patients and reputations. This evidence-based report offers a technical overview of disinfection strategies—including a comparison of UV and aerosolized hydrogen peroxide systems—and explains why Breezy Blue® is the most effective and practical solution for whole-room, touchless terminal cleaning.
Highlights include:
A side-by-side comparison of UV and aerosolized hydrogen peroxide efficacy, coverage, and usability
Clinical evidence demonstrating >99.9999% reduction of key pathogens including C. diff, MRSA, VRE, and SARS-CoV-2
How Breezy Cloud™ automates compliance reporting, helping hospitals meet CMS, NHSN, and Joint Commission requirements
Practical use cases: isolation room turnover, OR decontamination, ICU disinfection, and outbreak containment
If you’re an infection preventionist, hospital executive, or EVS manager looking for better disinfection results with less effort and lower cost, this clinical brief is for you.
👉 Download the full clinical brief here: Reducing the Cost & Risk of Healthcare-Associated infections